TAKE Limited Q1 FY27: Revenue ₹30.37 Cr, Profit ₹1.06 Cr; Enters Longevity Market
TAKE Limited reported Q1 FY27 consolidated revenue of ₹30.37 Crore and net profit of ₹1.06 Crore, a significant turnaround. Standalone revenue rose to ₹1,196.90 Lakhs with a profit of ₹96.83 Lakhs. The company has strategically entered the Longevity and Biohacking market.
The financial turnaround and the strategic diversification into a new, high-potential market are significant developments that will likely have a substantial impact on the company's future prospects.
The company has shown a strong turnaround in its financial performance, moving from losses to profits, and has announced a strategic expansion into a high-growth market.
TAKE Limited (formerly TAKE Solutions Limited) announced its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY27). The company reported a consolidated revenue from operations of ₹3,037.33 Lakhs (₹30.37 Crore), a significant increase from nil revenue in the corresponding prior-year period. Consolidated Net Profit After Tax (PAT) stood at ₹106.26 Lakhs (₹1.06 Crore), marking a turnaround from a net loss of ₹(91.00) Lakhs in Q1 FY26. Finance costs saw a drastic reduction of 99.62% YoY, decreasing to ₹0.07 Lakhs from ₹17.50 Lakhs in Q1 FY26. Basic and Diluted Earnings Per Share (EPS) turned positive at ₹0.07 per share.
On a standalone basis, revenue from operations surged to ₹1,196.90 Lakhs from ₹0.65 Lakhs in Q1 FY26, with Net Profit turning around to ₹96.83 Lakhs from a net loss of ₹(216.45) Lakhs in the same period last year.
The company also announced its strategic entry into the Longevity, Biohacking, and Preventive Healthcare market. This move leverages its expertise in life sciences, clinical research, and regulatory execution to tap into a rapidly growing global market projected to reach USD 67.03 Billion by 2035. The strategy integrates science-backed nutraceuticals and biohacking products with technology-enabled digital tools for health optimization.
Parmeshvar Dhangare, Director, TAKE Limited, commented, "Our Q1 FY27 results reflect the successful stabilization and revitalization of TAKE Limited's operational framework. With an extremely clean balance sheet, near-zero finance costs, and profitable operations, we are now executing our next growth phase. Our strategic entry into the Longevity and Anti-Ageing sector positions TAKE Limited at the intersection of life sciences, technology, and consumer wellness."
The Board Meeting, which commenced at 05:00 p.m. (IST) and concluded at 06:00 p.m. (IST) on August 11, 2026, also approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.
What to do with a filing like this
Take Solutions Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Take Solutions Limited. Read the original for the full detail.